Exact Sciences Corp EXAS
We take great care to ensure that the data presented and summarized in this overview for EXACT SCIENCES CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EXAS
View all-
Vanguard Group Inc Valley Forge, PA17.7MShares$922 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA13MShares$677 Million0.15% of portfolio
-
Jpmorgan Chase & CO New York, NY12.4MShares$643 Million0.08% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$591 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$555 Million0.13% of portfolio
-
State Street Corp Boston, MA5.09MShares$265 Million0.02% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl3.27MShares$170 Million1.61% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.11MShares$162 Million0.33% of portfolio
-
Geode Capital Management, LLC Boston, MA2.97MShares$154 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.95MShares$153 Million0.09% of portfolio
Latest Institutional Activity in EXAS
Top Purchases
Top Sells
About EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Insider Transactions at EXAS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 01
2024
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
1,155
-0.1%
|
$69,300
$60.15 P/Share
|
|
May 01
2024
|
Jacob A Orville General Manager, Screening |
SELL
Open market or private sale
|
Direct |
102
-0.7%
|
$6,120
$60.15 P/Share
|
|
May 01
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
102
-0.14%
|
$6,120
$60.15 P/Share
|
|
May 01
2024
|
Brian Baranick EVP, GM., Precision Oncology |
SELL
Open market or private sale
|
Direct |
110
-0.82%
|
$6,600
$60.15 P/Share
|
|
May 01
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
136
-1.14%
|
$8,160
$60.15 P/Share
|
|
May 01
2024
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
30
-0.3%
|
$1,800
$60.15 P/Share
|
|
May 01
2024
|
Everett Cunningham Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
136
-0.29%
|
$8,160
$60.15 P/Share
|
|
May 01
2024
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
67
-0.15%
|
$4,020
$60.15 P/Share
|
|
Apr 30
2024
|
Kevin T Conroy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,197
+0.14%
|
$47,955
$15.01 P/Share
|
|
Apr 30
2024
|
Jacob A Orville General Manager, Screening |
BUY
Grant, award, or other acquisition
|
Direct |
218
+1.48%
|
-
|
|
Apr 30
2024
|
Sarah Condella EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
926
+0.63%
|
$13,890
$15.01 P/Share
|
|
Apr 30
2024
|
Brian Baranick EVP, GM., Precision Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
218
+1.6%
|
-
|
|
Apr 30
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
998
+4.06%
|
$14,970
$15.01 P/Share
|
|
Apr 30
2024
|
James Herriott SVP, General Counsel & Sec |
BUY
Grant, award, or other acquisition
|
Direct |
771
+3.68%
|
$11,565
$15.01 P/Share
|
|
Apr 30
2024
|
Everett Cunningham Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
999
+1.05%
|
$14,985
$15.01 P/Share
|
|
Apr 30
2024
|
D Scott Coward |
BUY
Grant, award, or other acquisition
|
Direct |
218
+0.49%
|
-
|
|
Apr 02
2024
|
Brian Baranick EVP, GM., Precision Oncology |
SELL
Open market or private sale
|
Direct |
924
-6.56%
|
$72,996
$79.43 P/Share
|
|
Apr 01
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,000
-2.71%
|
$140,000
$70.0 P/Share
|
|
Mar 28
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,000
-2.64%
|
$140,000
$70.0 P/Share
|
|
Mar 01
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,412
-18.07%
|
$142,308
$59.32 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 87.7K shares |
|---|---|
| Exercise of conversion of derivative security | 284K shares |
| Payment of exercise price or tax liability | 61.6K shares |
|---|---|
| Open market or private sale | 181K shares |
| Bona fide gift | 2.39K shares |